SCHEMBL16295705

SCHEMBL16295705

O=C(Nc1ccnc(Nc2ccc(N3CCOCC3)cc2)n1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 5/20 0.72
▸ AURKA O14965 2/20 0.68
▸ MAPK8 P45983 1/20 0.68
▸ JAK2 O60674 6/20 0.62
▸ AURKB Q96GD4 1/20 0.61
▸ JAK3 P52333 2/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ NCOR1 O75376 1/20 0.61
▸ JAK1 P23458 1/20 0.61
▸ TYK2 P29597 1/20 0.61
▸ HDAC1 Q13547 1/20 0.61
▸ HDAC2 Q92769 1/20 0.61
▸ HDAC8 Q9BY41 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ EGFR P00533 2/20 0.61
▸ IGF1R P08069 3/20 0.58
▸ TP53 P04637 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ERBB2 P04626 1/20 0.56
▸ PLK1 P53350 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4387681 0.86 JAK2 (0.77) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL2565238 0.79 HDAC8 (0.76) HDAC8HDAC6TP53SMN1; SMN2MAPT
SCHEMBL4377173 0.78 JAK2 (0.77) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL4384955 0.78 JAK2 (0.77) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL13321202 0.77 EGFR (0.60) AURKAMAPK8JAK2AURKBEGFR
SCHEMBL13300660 0.77 EGFR (0.73) AURKAMAPK8AURKBEGFRIGF1R
SCHEMBL4390255 0.77 TP53 (0.72) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL2880178 0.77 JAK2 (0.72) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL4393244 0.77 JAK2 (0.78) PLK4MAPK8JAK2JAK3HDAC3
SCHEMBL4378132 0.76 JAK2 (0.77) PLK4MAPK8JAK2JAK3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3840752-A1 PLATELET COUNT-AGNOSTIC METHODS OF TREATING MYELOFIBROSIS Sierra Oncology, Inc. (US) 2021-06-30 — — EP disclosed
WO-2020041466-A1 PLATELET COUNT-AGNOSTIC METHODS OF TREATING MYELOFIBROSIS SIERRA ONCOLOGY, INC. (US) 2020-02-27 — — WO disclosed
WO-2014199166-A1 METHOD OF INCREASING VIRAL GROWTH RATE AND/OR TITRE IN CELLS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2014-12-18 — — WO disclosed
Send feedback